Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial. (PubMed, Nat Commun) - Mar 9, 2025 - P1/2 | "For ORR, 57.1% exhibited stable disease (SD), 4.8% partial response, and 38.1% progressive disease. Overall, patients received radiation absorbed doses without significant toxicity higher than possible with external beam radiation therapy (EBRT) and demonstrated mOS beyond standard of care for recurrent glioblastoma (~8 months)."
Journal • P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|
|
Ande Bao; Andrew J Brenner; Carlos Kamiya Matsuoka; Jeffrey S Weinberg; Joel E Michalek; John R Floyd; Marc H Hedrick; Melissa Moore; Michael Youssef; Norman LaFrance; Toral Patel; William T Phillips
|